Floatz logo

gp96

Liver Cancer

Cure&Sure Biotech Co., LTDUNKNOWNPhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

110 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Dexmedetomidine
Uppsala University Hospital
Phase 4BBB
Adriamycin
Shanghai Zhongshan Hospital
Phase 4BB
Xaliplatin
Sun Yat-sen University
Phase 3BB
Sufentanyl
The Second Affiliated Hospital of Chongqing Medical University
Phase 4BB
Idarubicin
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

gp96 is also rated in:

brain gliomaDormant
CCC
Indicative · Phase 2
53 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative · Phase 1/2
43 / 100
View asset →
gliomaDormant
CC
Indicative · Phase 1
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →